摘要
目的观察通心络胶囊联合沙库巴曲缬沙坦治疗左心相关性肺动脉高压(PH-LHD)的临床效果。方法选取2019年8~12月我院收治的108例PH-LHD患者,按入院顺序分为对照组、观察A组、观察B组,各36例。三组均给予常规治疗,对照组在常规治疗的基础上给予缬沙坦,观察A组在常规治疗的基础上给予沙库巴曲缬沙坦,观察B组在常规治疗的基础上给予沙库巴曲缬沙坦联合通心络胶囊。比较三组治疗3个月后的临床疗效、动脉血氧分压(PaO2)、肺动脉压[肺动脉收缩压(PASP)、肺动脉舒张压(PADP)]。结果观察B组的治疗有效率均高于观察A组与对照组,差异有统计学意义(P<0.05)。三组治疗后的PaO2水平均高于治疗前,差异有统计学意义(P<0.05)。观察B组治疗后的PaO2水平高于观察A组与对照组,差异有统计学意义(P<0.05)。三组治疗后的PASP、PADP水平均低于治疗前,差异有统计学意义(P<0.05)。观察B组治疗后的PASP、PADP水平低于观察A组与对照组,差异有统计学意义(P<0.05)。结论通心络胶囊联合沙库巴曲缬沙坦治疗PH-LHD可提高临床效果,改善动脉PaO2及肺动脉压,值得临床推广应用。
Objective To observe the clinical effect of Tongxinluo Capsules combined with Sacubitril and Valsartan in the treatment of pulmonary hypertension due to left heart disease(PH-LHD).Methods A total of 108 patients with PH-LHD who admitted in our hospital from August to December 2019 were selected and randomly divided into the control group,the observation group A and the observation group B,with 36 cases in each group.Three groups were given routine treatment,the control group was given Valsartan based on routine treatment,the observation group A was given Sacubitril and Valsartan based on routine treatment,and the observation group B was treated with Sacubitril and Valsartan combined with Tongxinluo Capsules based on routine treatment.After treatment for 3 months,the clinical efficacy,arterial partial pressure of oxygen(PaO2),pulmonary arterial pressure(pulmonary arterial systolic pressure[PASP],pulmonary arterial diastolic pressure[PADP])were compared among the three groups.Results The effective rate of the observation group B were higher than those of the observation group A and the control group,the differences were statistically significant(P<0.05).The level of PaO2 in the three groups after treatment were higher than those before treatment,the differences were statistically significant(P<0.05).The level of PaO2 in the observation group B was higher than that in the observation group A and the control group,the differences were statistically significant(P<0.05).After treatment,the level of PASP and PADP of the three groups were lower than those before treatment,the differences were statistically significant(P<0.05).The levels of PASP and PADP in the observation group B were lower than those in the observation group A and the control group,the differences were statistically significant(P<0.05).Conclusion Tongxinluo capsule combined with Sacubitril and Valsartan in the treatment of PH-LHD can increase clinical efficacy,and improve PaO2 and pulmonary arterial pressure,which is worthy of clinical promotion and application.
作者
汤曾耀
梅寒颖
刘继文
王新旺
朱保成
刘玉连
TANG Zeng-yao;MEI Han-ying;LIU Ji-wen;WANG Xin-wang;ZHU Bao-cheng;LIU Yu-lian(Department of Cardiovascular Medicine,Jiujiang First People′s Hospital,Jiangxi Province,Jiujiang332000,China)
出处
《中国当代医药》
2020年第29期29-31,48,共4页
China Modern Medicine
基金
江西省中医药科研课题(2019A407)。
关键词
左心相关性肺动脉高压
通心络胶囊
沙库巴曲缬沙坦
动脉血氧分压
肺动脉收缩压
肺动脉舒张压
Pulmonary hypertension due to left heart disease
Tongxinluo Capsules
Sacubitril and Valsartan
Arterial partial pressure of oxygen
Pulmonary arterial systolic pressure
Pulmonary arterial diastolic pressure
